Lupus

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, highlighted two important studies presented at ACR 2020.

BIIB059 significantly reduces total active joint counts among patients with systemic lupus erythematosus, with a rate of serious adverse events and infection similar to placebo, according to a speaker at ACR Convergence 2020.

Optimizing patient-provider communication and enhancing patient self-efficacy may improve medication adherence rates among patients with systemic lupus erythematosus, according to results presented at the ACR Convergence 2020 meeting.

Anifrolumab is superior to placebo for improved BILAG-2004 and SLEDAI-2K domain scores, as well as in mucocutaneous and musculoskeletal domains, among patients with systemic lupus erythematosus, according to a speaker at ACR Convergence.

Treatment with hydroxychloroquine does not impact corrected QT length among patients with rheumatoid arthritis or systemic lupus erythematosus, even after adjusting for confounders, according to a speaker at ACR Convergence.

Obinutuzumab provides sustained clinical benefit through 2 years among patients with lupus nephritis, with treatment efficacy maintained 18 months after the final infusion, according to data presented at ACR 2020.

Among Black patients with lupus, the risk for stroke is three times higher than white patients, and the risk for ischemic heart disease is 24 times higher, according to a presenter at ACR Convergence 2020 virtual meeting.

Simple, standardized outcome measures, including steroid-sparing, could advance lupus drug development, while clarifying the lupus spectrum may improve diagnosis time and patient understanding, according to a speaker at ACR Convergence.

Patients with systemic lupus erythematosus, especially those who are positive for anti-Sm antibodies, are at greater risk for adverse events associated with trimethoprim-sulfamethoxazole, according to data presented at the ACR Convergence 2020 virtual meeting.

Corrected QT interval was unaffected by hydroxychloroquine use in patients with systemic lupus erythematosus — both with and without chronic kidney disease, according to data presented at the ACR Convergence 2020 virtual meeting.